分享好友 环球市场首页 环球市场分类 切换频道

Liver Cancer Drugs Market

2025-08-2100

Report Overview

Global Liver Cancer Drugs Market size is expected to be worth around US$ 16.39 Billion by 2034 from US$ 3.78 Billion in 2024, growing at a CAGR of 15.8% during the forecast period 2025 to 2034. In 2024, North America led the market, achieving over 38.8% share with a revenue of US$ 1.47 Billion.

The liver cancer drugs market is experiencing significant growth, driven by the increasing prevalence of liver cancer worldwide. Hepatocellular carcinoma (HCC), the most common form of liver cancer, is largely caused by risk factors such as chronic hepatitis B and C, alcohol consumption, and non-alcoholic fatty liver disease.

With over 800,000 new cases diagnosed annually, the demand for effective treatments continues to rise. The market is dominated by targeted therapies like sorafenib (Nexavar) and lenvatinib (Lenvima), as well as immunotherapies such as nivolumab (Opdivo) and pembrolizumab (Keytruda), which have significantly improved survival rates for patients with advanced liver cancer. The growth of the market is further supported by ongoing research into innovative drug combinations and novel treatment modalities, such as personalized medicine and combination therapies.

Liver Cancer Drugs Market Size

However, the high cost of treatments remains a key challenge, limiting access for patients in low- and middle-income countries. Despite this, the development of biosimilars and generic versions of existing drugs is expected to ease cost burdens in the coming years. As healthcare systems globally improve and more patients gain access to modern therapies, the liver cancer drugs market is projected to continue expanding, with an increasing focus on improving patient outcomes through more targeted and efficient treatment strategies.

Food and Drug Administration (FDA) has approved a number of drugs for liver cancer, below is the list:

Key Market Segments

By Drug Class

  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy
  • Others

By Cancer Type

  • Hepatocellular Carcinoma (HCC)
  • Cholangiocarcinoma
  • Hepatoblastoma
  • Others

By Route of Administration

  • Oral
  • Injectable

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Drivers

Increasing Incidence of Liver Cancer

The rising global incidence of liver cancer is a significant driver for the liver cancer drugs market. As the prevalence of risk factors such as hepatitis B and C, alcohol consumption, and obesity continues to grow, liver cancer cases are on the rise, particularly in regions like Asia-Pacific. According to the World Health Organization (WHO), liver cancer is the sixth most common cancer worldwide, with over 800,000 new cases annually. This increased incidence boosts the demand for effective treatments, creating substantial growth opportunities for pharmaceutical companies.

For example, drugs like sorafenib (Nexavar) and lenvatinib (Lenvima) are currently leading treatments, and their market success is driven by the growing number of liver cancer patients seeking innovative therapies. According to World Cancer Research Fund, there were 866,136 new cases of liver cancer in 2022.

Liver cancer incidence (cases), 2022

Key Regions and Countries

North America

  • US
  • Canada

Europe

  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Russia
  • Netherland
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • South Korea
  • India
  • Australia
  • New Zealand
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA

Key Players Analysis

Key players in the Liver Cancer Drugs market includes Bayer AG, Bristol-Myers Squibb, Merck & Co., Inc., Pfizer Inc., Exelixis, Inc., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Novartis AG, AstraZeneca, Ipsen, Sirtex Medical, Gilead Sciences, BeiGene, Innovent Biologics, Sumitomo Pharma, Hepion Pharmaceuticals, and Others.

Pfizer is a leading global biopharmaceutical company involved in liver cancer drug development. They focus on targeted therapies, particularly in immuno-oncology. Pfizer’s collaboration with Merck in clinical trials for liver cancer treatments has expanded the use of Atezolizumab (Tecentriq), a prominent immunotherapy for liver cancer.

Exelixis is known for developing Cabometyx (cabozantinib), a key targeted therapy for liver cancer. Cabometyx is used to treat advanced hepatocellular carcinoma (HCC), particularly for patients who have previously been treated with sorafenib. Exelixis is actively involved in clinical trials to expand its liver cancer drug portfolio.

Eisai, a Japanese pharmaceutical company, manufactures Lenvima (lenvatinib), a highly effective targeted therapy for advanced liver cancer. Lenvima has shown positive results in clinical trials and is approved for first-line treatment in combination with immunotherapy for hepatocellular carcinoma (HCC), demonstrating improved patient survival outcomes.

Top Key Players

  • Bayer AG
  • Bristol-Myers Squibb
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Exelixis, Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Hoffmann-La Roche Ltd
  • Novartis AG
  • AstraZeneca
  • Ipsen
  • Sirtex Medical
  • Gilead Sciences
  • BeiGene
  • Innovent Biologics
  • Sumitomo Pharma
  • Hepion Pharmaceuticals
  • Others

Key Opinion Leaders:

Dr. Mark Johnson, Senior Oncologist at Memorial Hospital, USADr. Laura Adams, Clinical Investigator and Hepatology Specialist, UKDr. Richard Lee, Medical Director, Oncology Research Group, Germany“Eisai’s Lenvima (lenvatinib) has become a key player in the treatment landscape for advanced liver cancer. It offers a potent option for patients, particularly when used in combination with immunotherapy. The combination of Lenvima with Pembrolizumab (Keytruda) has shown exceptional results in clinical trials, positioning Eisai as a leader in combination therapies. Lenvima’s approval as a first-line treatment for hepatocellular carcinoma has made it a first-choice drug in many oncology centers, and the data supporting its efficacy continues to grow.”

Recent Developments

  • In December 2024, Medivir AB, a pharmaceutical company dedicated to developing innovative cancer treatments for high unmet medical needs, today announced the approval of its US Investigational New Drug (IND) application. This approval allows the evaluation of fostrox in combination with Lenvima, versus Lenvima alone, in a Phase 2b study for second-line advanced hepatocellular carcinoma (HCC).
  • In September 2024, updated results from the HIMALAYA Phase III trial revealed that AstraZeneca’s Imfinzi (durvalumab) combined with Imjudo (tremelimumab) showed a sustained and clinically meaningful overall survival (OS) benefit at five years for patients with unresectable hepatocellular carcinoma (HCC) who had not previously received systemic therapy and were ineligible for localized treatment. These significant findings from the HIMALAYA trial will be presented today at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain (presentation 947MO).
  • In October 2022, the FDA approved the combination of tremelimumab (Imjudo, AstraZeneca) and durvalumab (Imfinzi, AstraZeneca) for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer.
举报
收藏 0
评论 0